Intest Res.  2022 Jul;20(3):361-369. 10.5217/ir.2021.00126.

Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests

Affiliations
  • 1Department of Digestive Medicine, Doctor Peset University Hospital, Valencia, Spain
  • 2Department of Radiology, Doctor Peset University Hospital, Valencia, Spain
  • 3Department of Pharmacy, Doctor Peset University Hospital, Valencia, Spain

Abstract

Background/Aims
Tight control of inflammation and adjustment of treatment if activity persists is the current strategy for the management of Crohn’s disease (CD). The usefulness of fecal calprotectin (FC) in isolated involvement of the small intestine in CD is controversial. To assess the usefulness of FC to determine the inflammatory activity detected by intestinal ultrasonography (IUS) in ileal CD.
Methods
Patients with exclusively ileal involvement CD who underwent IUS and an FC were prospectively included. Simple ultrasound index was used to determine inflammatory activity. The usual statistical tests for comparison of diagnostic techniques were used.
Results
One hundred and five patients were included, IUS showed inflammatory activity in 59% of patients and complications in 18.1%. FC showed a significant correlation with IUS in the weak range (Spearman coefficient r=0.502; P<0.001); the area under the receiver operating characteristic curve was 0.79 (95% confidence interval, 0.70–0.88; P<0.001). The FC value that best reflected the activity in IUS was 100 μg/g with sensitivity, specificity, and positive and negative predictive values of 73.0%, 71.4%, 79.3% and 63.8%, respectively. There were no differences in FC concentration between patients with or without transmural complications. The addition of serum C-reactive protein to FC did not improve the ability to assess IUS activity.
Conclusions
FC has a significant correlation with IUS to monitor ileal CD activity. This correlation is weak and it does not allow assessing the presence of CD complications. Both tests should be used in conjunction for tight control of ileal CD. More studies on noninvasive tests in this location are needed.

Keyword

Crohn disease; Tight control; Intestinal ultrasonography; Fecal calprotectin

Figure

  • Fig. 1. Flowchart showing the number of patients entering the study. IUS, intestinal ultrasonography.

  • Fig. 2. Fecal calprotectin receiver operating characteristic curve for assess inflammatory activity in intestinal ultrasonography of ileal Crohn´s disease. AUC, area under the receiver operating characteristic curve.

  • Fig. 3. Correlation between fecal calprotectin and different ultrasound variables. (A) Correlation between simple ultrasound score and fecal calprotectin concentration. (B) Linear correlation between the wall thickness and fecal calprotectin concentration (95% confidence interval, CI).


Reference

1. Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019; 68:423–433.
Article
2. Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: what do we mean by “tight control”? World J Gastroenterol. 2019; 25:6172–6189.
Article
3. Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016; 43:317–333.
Article
4. Allocca M, Danese S, Laurent V, Peyrin-Biroulet L. Use of cross-sectional imaging for tight monitoring of inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020; 18:1309–1323.
5. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18:2218–2224.
Article
6. Bryant RV, Friedman AB, Wright EK, et al. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut. 2018; 67:973–985.
Article
7. Ripollés T, Poza J, Suarez Ferrer C, Martínez-Pérez MJ, Martín-Algíbez A, de Las Heras Paez B. Evaluation of Crohn’s disease activity: development of an ultrasound score in a multicenter study. Inflamm Bowel Dis. 2021; 27:145–154.
Article
8. Castiglione F, Imperatore N, Testa A, et al. One-year clinical outcomes with biologics in Crohn’s disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther. 2019; 49:1026–1039.
Article
9. Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016; 44:495–504.
Article
10. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017; 390:2779–2789.
Article
11. Dulai PS, Singh S, Vande Casteele N, et al. Should we divide Crohn’s disease into ileum-dominant and isolated colonic diseases? Clin Gastroenterol Hepatol. 2019; 17:2634–2643.
Article
12. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008; 14:40–46.
Article
13. Gecse KB, Brandse JF, van Wilpe S, et al. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand J Gastroenterol. 2015; 50:841–847.
Article
14. Simon EG, Wardle R, Thi AA, Eldridge J, Samuel S, Moran GW. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease? A systematic review. Intest Res. 2019; 17:160–170.
Article
15. Makanyanga JC, Pendsé D, Dikaios N, et al. Evaluation of Crohn’s disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol. 2014; 24:277–287.
Article
16. Cerrillo E, Beltrán B, Pous S, et al. Fecal calprotectin in ileal Crohn’s disease: relationship with magnetic resonance enterography and a pathology score. Inflamm Bowel Dis. 2015; 21:1572–1579.
17. Ye L, Cheng W, Chen BQ, et al. Levels of faecal calprotectin and magnetic resonance enterocolonography correlate with severity of small bowel Crohn’s disease: a retrospective cohort study. Sci Rep. 2017; 7:1970.
Article
18. Zittan E, Kelly OB, Gralnek IM, Silverberg MS, Hillary Steinhart A. Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn’s disease activity. JGH Open. 2018; 2:201–206.
Article
19. Jones GR, Fascì-Spurio F, Kennedy NA, et al. Faecal calprotectin and magnetic resonance enterography in ileal Crohn’s disease: correlations between disease activity and long-term follow-up. J Crohns Colitis. 2019; 13:442–450.
Article
20. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170:2–6.
Article
21. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010; 8:357–363.
Article
22. Reenaers C, Bossuyt P, Hindryckx P, Vanpoucke H, Cremer A, Baert F. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J. 2018; 6:1117–1125.
Article
23. Nylund K, Maconi G, Hollerweger A, et al. EFSUMB recommendations and guidelines for gastrointestinal ultrasound. Ultraschall Med. 2017; 38:273–284.
24. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta-analysis. Radiology. 2005; 236:95–101.
Article
25. Patriquin HB, Garcier JM, Lafortune M, et al. Appendicitis in children and young adults: Doppler sonographic-pathologic correlation. AJR Am J Roentgenol. 1996; 166:629–633.
Article
26. Panés J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011; 34:125–145.
Article
27. Watanabe K. Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intest Res. 2020; 18:347–354.
Article
28. Dillman JR, Dehkordy SF, Smith EA, et al. Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy. Pediatr Radiol. 2017; 47:924–934.
Article
29. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160:1570–1583.
Article
30. Mak LY, Tong TS, Cheung KS, et al. Combined use of common fecal and blood markers for detection of endoscopically active inflammatory bowel disease. Clin Transl Gastroenterol. 2020; 11:e00138.
Article
Full Text Links
  • IR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr